Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.5818
Abstract: Importance Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms. Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib. Objective To compare the… read more here.
Keywords: patients patients; pacritinib; including ruxolitinib; bat ... See more keywords
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib
Sign Up to like & getrecommendations! Published in 2020 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-020-00596-z
Abstract: Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with… read more here.
Keywords: pacritinib; jak; generation jak; myeloproliferative neoplasms ... See more keywords
Pacritinib protects dendritic cells more efficiently than ruxolitinib.
Sign Up to like & getrecommendations! Published in 2021 at "Experimental hematology"
DOI: 10.1016/j.exphem.2021.06.004
Abstract: Targeting Januskinase (JAK) has revolutionized the treatment of myeloproliferative neoplasms. The JAK inhibitor ruxolitinib improved the outcome and quality of life of patients dramatically at the cost of increased risk of infections. As previously shown,… read more here.
Keywords: pacritinib; ruxolitinib pacritinib; jak inhibitor; dendritic cells ... See more keywords
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0112-2
Abstract: Interleukin-1 receptor-associated kinase 1 (IRAK1), an essential mediator of innate immunity and inflammatory responses, is constitutively active in multiple cancers. We evaluated the role of IRAK1 in acute myeloid leukemia (AML) and assessed the inhibitory… read more here.
Keywords: pacritinib; irak1; kinase; aml ... See more keywords
Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
Sign Up to like & getrecommendations! Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0222944
Abstract: Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling is critical to multiple cellular processes, including survival, differentiation, and proliferation. JAK-STAT signaling dysregulation has been noted in inflammatory disorders, and aberrant JAK2 pathway activation has… read more here.
Keywords: pacritinib; momelotinib pacritinib; jak2 inhibitors; momelotinib ... See more keywords
First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer agents in medicinal chemistry"
DOI: 10.2174/1871520623666230320120915
Abstract: In this short perspective, the chemical structure, physical properties, synthesis, mechanism of action, and pharmacokinetic profile of pacritinib are summarized. It is an orally bioavailable and isoform-selective JAK-2 inhibitor for treating patients with myelofibrosis. read more here.
Keywords: inhibitor; pacritinib selective; pacritinib; first approval ... See more keywords